Compare Eli Lilly And Co (LLY) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Tidewater Inc — how do they compare? Eli Lilly And Co trades at $1,163.09 (market cap $1.02T), while Tidewater Inc trades at $78.75 (market cap $3.75B). The key difference: Eli Lilly And Co is far larger — about 272× Tidewater Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| LLY | TDW | |
|---|---|---|
Market Cap | $1.02T | $3.75B |
Sector | Health | Utilities |
52-Week High | $1.24K | $91.12 |
52-Week Low | $625.65 | $47.29 |
Enterprise Value | $1.06T | $3.85B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Tidewater (TDW) trades at $75.43, down 0.51% today, with a bullish technical outlook supported by moving averages but recent earnings misses in Q1 and Q4 2026. The company maintains strong profitability with a 22.16% net margin and a P/E of 12.79, while news highlights an acquisition by FTAI Infrastructure (GlobeNewsWire, June 29, 2026).
Outlook is mixed: valuation appears reasonable with solid cash flow, but earnings volatility and sector headwinds pose risks. Analyst consensus leans hold (61.54%), suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
